MX340234B - Tratamiento para transtornos gastrointestinales. - Google Patents
Tratamiento para transtornos gastrointestinales.Info
- Publication number
- MX340234B MX340234B MX2012009597A MX2012009597A MX340234B MX 340234 B MX340234 B MX 340234B MX 2012009597 A MX2012009597 A MX 2012009597A MX 2012009597 A MX2012009597 A MX 2012009597A MX 340234 B MX340234 B MX 340234B
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- disease
- conditions
- obstruction
- gastrointestinal disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a péptidos, composiciones, y métodos relacionados para tratar trastornos y condiciones gastrointestinales, que incluyen pero no se limitan a, síndrome del intestino irritable (lBS), trastornos de movilidad gastrointestinal, trastornos gastrointestinales funcionales, enfermedad de reflujo gastroesofageal (GERD), reflujo duodenogástrico, enfermedad de Crohn, colitis ulcerativa, enfermedad inflamatoria del intestino, acidez funcional, dispepsia, dolor visceral, gastropáresis, pseudo-obstrucción intestinal crónica (o pseudo-obstrucción colónica), trastornos y condiciones asociadas con estreñimiento, y otras condiciones o trastornos son descritos en la presente, usando péptidos y otros agentes que activan al receptor de guanilato ciclasa C (GC-C).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30546510P | 2010-02-17 | 2010-02-17 | |
PCT/US2011/025274 WO2011103311A2 (en) | 2010-02-17 | 2011-02-17 | Treatments for gastrointestinal disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012009597A MX2012009597A (es) | 2012-09-28 |
MX340234B true MX340234B (es) | 2016-07-01 |
Family
ID=43875305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012009597A MX340234B (es) | 2010-02-17 | 2011-02-17 | Tratamiento para transtornos gastrointestinales. |
Country Status (13)
Country | Link |
---|---|
US (6) | US8933030B2 (es) |
EP (1) | EP2536742B1 (es) |
CN (1) | CN102869677B (es) |
AU (3) | AU2011218009B2 (es) |
CA (1) | CA2790213A1 (es) |
DK (1) | DK2536742T3 (es) |
EA (1) | EA201290799A1 (es) |
ES (1) | ES2638589T3 (es) |
MX (1) | MX340234B (es) |
PL (1) | PL2536742T3 (es) |
TR (1) | TR201711271T4 (es) |
UA (1) | UA108636C2 (es) |
WO (1) | WO2011103311A2 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103702678A (zh) * | 2010-09-11 | 2014-04-02 | 硬木药品公司 | 便秘型肠易激综合征的治疗 |
PL2776055T3 (pl) | 2011-08-17 | 2017-06-30 | Ironwood Pharmaceuticals, Inc. | Sposoby leczenia zaburzeń żołądkowo-jelitowych |
CN102875655B (zh) * | 2012-09-29 | 2014-12-17 | 深圳翰宇药业股份有限公司 | 一种合成利那洛肽的方法 |
CN104231051B (zh) * | 2013-06-06 | 2020-06-26 | 深圳翰宇药业股份有限公司 | 一种利那洛肽的制备方法 |
MX2016001714A (es) | 2013-08-09 | 2016-10-03 | Ardelyx Inc | Compuestos y metodos para inhibir el transporte de fosfato. |
UA119335C2 (uk) * | 2013-12-11 | 2019-06-10 | Айронвуд Фармасьютикалз, Інк. | Композиції лінаклотиду з затриманим вивільненням |
WO2015166468A1 (en) * | 2014-05-02 | 2015-11-05 | Sinoveda Canada, Inc. | Formulas comprising highly soluble elements and vitamin d for the prevention and treatment of bowel conditions during calcium supplementation |
PL3288578T3 (pl) * | 2015-05-01 | 2023-08-14 | Ironwood Pharmaceuticals, Inc. | Kompozycje do oczyszczania okrężnicy i leczenia zaburzeń przewodu pokarmowego |
BR112019012689A2 (pt) | 2016-12-21 | 2019-11-19 | Ironwood Pharmaceuticals Inc | métodos de tratamento da síndrome do intestino irritável com formulações de linaclotide modificada ou de liberação prolongada |
US10695402B2 (en) | 2017-03-16 | 2020-06-30 | University Of Rochester | Erythropoietin for gastrointestinal dysfunction |
CN106831950A (zh) * | 2017-03-18 | 2017-06-13 | 南京工业大学 | 一种制备利那洛肽的方法 |
IT201700054380A1 (it) * | 2017-05-19 | 2018-11-19 | Aboca Spa Societa Agricola | Composizioni contenenti sistemi di rilascio di anidride carbonica ottenuti da succhi vegetali |
JP2022533251A (ja) | 2019-05-21 | 2022-07-21 | アルデリックス, インコーポレイテッド | 患者において血清リン酸塩を低下させるための組み合わせ |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH658973A5 (fr) | 1983-12-29 | 1986-12-31 | Nestle Sa | Produit aromatisant. |
JPS6197229A (ja) | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
DE3729863A1 (de) | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
JPS649938A (en) | 1987-06-30 | 1989-01-13 | Agency Ind Science Techn | Oral ingestive composition |
EP0420964A4 (en) | 1989-04-11 | 1991-09-25 | Immunobiology Research Institute, Inc. | Lyophilized peptide formulations |
IT1240314B (it) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | Formulazioni acquose stabilizzate di piccoli peptidi. |
US5221495A (en) | 1990-04-13 | 1993-06-22 | Colgate-Palmolive Company | Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions |
US5451410A (en) | 1993-04-22 | 1995-09-19 | Emisphere Technologies, Inc. | Modified amino acids for encapsulating active agents |
US6284727B1 (en) | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5654278A (en) | 1994-10-13 | 1997-08-05 | Novo Nordisk A/S | Composition and method comprising growth hormone and leucine |
US5593696A (en) | 1994-11-21 | 1997-01-14 | Mcneil-Ppc, Inc. | Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders |
CH689139A5 (de) | 1995-04-03 | 1998-10-30 | Cerbios Pharma Sa | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung. |
US5904935A (en) | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
IL127769A (en) | 1996-07-03 | 2006-10-31 | Alza Corp | Non-aqueous protic preparations of peptides |
US5932547A (en) | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
US5916582A (en) | 1996-07-03 | 1999-06-29 | Alza Corporation | Aqueous formulations of peptides |
US6541606B2 (en) | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
US6087478A (en) | 1998-01-23 | 2000-07-11 | The Rockefeller University | Crystal of the N-terminal domain of a STAT protein and methods of use thereof |
JP2002521322A (ja) | 1998-07-23 | 2002-07-16 | ノボ ノルディスク アクティーゼルスカブ | 安定な医薬製剤の製造のための湿式顆粒化方法 |
AU766293B2 (en) | 1998-11-27 | 2003-10-16 | Kanji Takada | An oral formulation for gastrointestinal drug delivery |
WO2001052937A1 (en) | 2000-01-24 | 2001-07-26 | Medtronic Minimed, Inc. | Mixed buffer system for stabilizing polypeptide formulations |
HUP0301802A3 (en) | 2000-06-28 | 2009-04-28 | Teva Pharma | Process for producing carvedilol, crystalline carvedilol, process for producing it and pharmaceutical composition containing it |
FR2811884B1 (fr) | 2000-07-21 | 2003-01-31 | Oreal | Utilisation en cosmetique de betainates d'amidon et composition les comprenant associes a au moins un agent benefique pour les matieres keratiniques |
US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
WO2002026248A1 (en) | 2000-09-29 | 2002-04-04 | Cognetix, Inc. | Stable peptide formulations |
ES2281458T3 (es) | 2000-12-21 | 2007-10-01 | Nektar Therapeutics | Composiciones de polvo estables en almacenamiento del receptor de interleucina 4. |
JP2004521123A (ja) | 2001-02-02 | 2004-07-15 | ファルマシア・コーポレーション | 腸癌阻害のためのウログアニリンおよびシクロオキシゲナーゼ−2阻害薬の組合わせ |
GB0104371D0 (en) | 2001-02-22 | 2001-04-11 | Clariant Int Ltd | Color improving stabilizing compositions comprising leucine |
US6573237B2 (en) | 2001-03-16 | 2003-06-03 | Eli Lilly And Company | Protein formulations |
CN103638514A (zh) | 2001-03-29 | 2014-03-19 | 药物协和公司 | 用于治疗组织炎症和癌变的鸟苷酸环化酶受体激动剂 |
WO2003014304A2 (en) | 2001-08-09 | 2003-02-20 | Doctor's Signature Sales And Marketing International Corp. [(Dba)] Life Force International | Protonic formulation |
US20030104996A1 (en) | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
US20040161776A1 (en) | 2001-10-23 | 2004-08-19 | Maddon Paul J. | PSMA formulations and uses thereof |
IL162618A0 (en) | 2001-12-21 | 2005-11-20 | Novo Nordisk As | Liquid composition of modified factor vii polypeptides |
JP2003201256A (ja) | 2001-12-28 | 2003-07-18 | Hisamitsu Pharmaceut Co Inc | 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤 |
DE10261126A1 (de) | 2002-08-13 | 2004-03-04 | Aventis Behring Gmbh | Lagerungsstabile, flüssige Fibrinogen-Formulierung |
KR20050088311A (ko) | 2002-12-11 | 2005-09-05 | 화이자 프로덕츠 인크. | 고지방 환경 내로의 활성 물질의 조절-방출 |
US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
DK2246360T3 (da) | 2003-01-28 | 2012-08-13 | Ironwood Pharmaceuticals Inc | Sammensætninger til behandlingen af gastrointestinale lidelser |
US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
DK1638586T3 (da) | 2003-05-14 | 2008-06-23 | Indus Biotech Pvt Ltd | Synergistisk sammensætning til behandling af diabetes mellitus |
KR100610003B1 (ko) | 2003-06-10 | 2006-08-08 | 주식회사 엘지생명과학 | 혈청 알부민을 함유하지 않는 안정한 인 에리쓰로포이에틴용액 제형 |
PL1644021T3 (pl) | 2003-06-13 | 2013-01-31 | Ironwood Pharmaceuticals Inc | Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych |
US7494979B2 (en) | 2003-06-13 | 2009-02-24 | Ironwood Pharmaceuticals, Inc. | Method for treating congestive heart failure and other disorders |
KR100560697B1 (ko) | 2003-08-06 | 2006-03-16 | 씨제이 주식회사 | 알부민을 함유하지 않는 에리스로포이에틴 제제 |
DE202004020676U1 (de) | 2004-03-10 | 2005-11-10 | Bioceuticals Arzneimittel Ag | Erythropoietin-Flüssigformulierung |
JP4744533B2 (ja) | 2004-12-30 | 2011-08-10 | ドゥビエル カンパニー リミテッド | 噴霧乾燥高分子型コレクチン属タンパク質及びその製造方法 |
US20090253634A1 (en) | 2005-08-19 | 2009-10-08 | Microbia, Inc. | Methods and Compositions for the Treatment of Gastrointestinal Disorders |
WO2007044375A2 (en) | 2005-10-06 | 2007-04-19 | Nastech Pharmaceutical Company Inc. | Pth formulations and methods of use |
CA2642761A1 (en) | 2006-02-23 | 2007-08-30 | Iomedix Sleep International Srl | Compositions and methods for the induction and maintenance of quality sleep |
US20090305993A1 (en) | 2006-02-24 | 2009-12-10 | Ironwood Pharmaceuticals, Inc. | Methods and composition for the treatment of gastrointestinal disorders |
ITMI20060629A1 (it) | 2006-03-31 | 2007-10-01 | Daniele Giovannone | Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento |
ES2532392T3 (es) | 2006-07-10 | 2015-03-26 | Pba3 Biomed Gmbh | Péptidos antimicrobianos |
EP3421031A1 (en) | 2006-08-09 | 2019-01-02 | Intarcia Therapeutics, Inc | Osmotic delivery systems and piston assemblies |
JP5042312B2 (ja) | 2006-08-31 | 2012-10-03 | ノバルティス アーゲー | Hghを含む経口送達用医薬組成物 |
CA2673260A1 (en) | 2006-12-20 | 2008-07-03 | Bayer Healthcare Llc | Factor vii and viia compositions |
EP2129683A4 (en) | 2007-02-26 | 2011-01-05 | Ironwood Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR TREATMENT OF HEART FAILURE AND OTHER DISORDERS |
EA020466B1 (ru) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний |
SI2328601T1 (sl) | 2008-08-15 | 2020-08-31 | Ironwood Pharmaceuticals, Inc. | Linaklotid vsebujoče formulacije za oralno dajanje |
EP2331077A2 (en) | 2008-09-04 | 2011-06-15 | Ironwood Pharmaceuticals, Inc. | Stable forlulation comprising therapeutic polypeptides for oral administration |
EP2341898A2 (en) | 2008-09-04 | 2011-07-13 | Ironwood Pharmaceuticals, Inc. | Stable solid formulations of gc-c receptor agonist polypeptides suitable for oral administration |
JP5964589B2 (ja) | 2008-12-03 | 2016-08-03 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcアゴニストの製剤およびその使用方法 |
US20130012454A1 (en) * | 2009-07-06 | 2013-01-10 | Ironwood Pharmaceuticals, Inc. | Orally Disintegrating Compositions of Linaclotide |
JP2013501071A (ja) | 2009-08-06 | 2013-01-10 | アイロンウッド ファーマシューティカルズ, インコーポレイテッド | リナクロチドを含む処方物 |
MX2012001691A (es) | 2009-08-12 | 2012-02-29 | Forest Lab Holdings Ltd | Composiciones de linaclotida que se desintegran oralmente. |
CA2780337A1 (en) | 2009-11-03 | 2011-05-12 | Ironwood Pharmaceuticals, Inc. | Linaclotide for the treatment of chronic constipation |
-
2011
- 2011-02-17 PL PL11706694T patent/PL2536742T3/pl unknown
- 2011-02-17 CN CN201180019529.2A patent/CN102869677B/zh active Active
- 2011-02-17 US US13/579,685 patent/US8933030B2/en active Active
- 2011-02-17 WO PCT/US2011/025274 patent/WO2011103311A2/en active Application Filing
- 2011-02-17 AU AU2011218009A patent/AU2011218009B2/en active Active
- 2011-02-17 TR TR2017/11271T patent/TR201711271T4/tr unknown
- 2011-02-17 EA EA201290799A patent/EA201290799A1/ru unknown
- 2011-02-17 UA UAA201210757A patent/UA108636C2/ru unknown
- 2011-02-17 ES ES11706694.4T patent/ES2638589T3/es active Active
- 2011-02-17 MX MX2012009597A patent/MX340234B/es active IP Right Grant
- 2011-02-17 CA CA2790213A patent/CA2790213A1/en not_active Abandoned
- 2011-02-17 DK DK11706694.4T patent/DK2536742T3/en active
- 2011-02-17 EP EP11706694.4A patent/EP2536742B1/en active Active
-
2014
- 2014-12-01 US US14/556,573 patent/US20150094265A1/en not_active Abandoned
-
2017
- 2017-01-30 AU AU2017200588A patent/AU2017200588A1/en not_active Abandoned
-
2019
- 2019-03-25 AU AU2019202052A patent/AU2019202052A1/en not_active Abandoned
-
2020
- 2020-05-22 US US16/881,198 patent/US20200283479A1/en not_active Abandoned
-
2021
- 2021-08-27 US US17/459,451 patent/US20210388026A1/en not_active Abandoned
-
2022
- 2022-04-08 US US17/716,560 patent/US20220227812A1/en not_active Abandoned
-
2023
- 2023-06-16 US US18/336,104 patent/US20230340025A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20140073571A9 (en) | 2014-03-13 |
US20210388026A1 (en) | 2021-12-16 |
US20130190238A1 (en) | 2013-07-25 |
US20230340025A1 (en) | 2023-10-26 |
EA201290799A1 (ru) | 2013-03-29 |
AU2017200588A1 (en) | 2017-02-23 |
ES2638589T3 (es) | 2017-10-23 |
AU2019202052A1 (en) | 2019-04-18 |
US20150094265A1 (en) | 2015-04-02 |
AU2011218009B2 (en) | 2016-11-03 |
CN102869677B (zh) | 2015-07-08 |
UA108636C2 (xx) | 2015-05-25 |
US8933030B2 (en) | 2015-01-13 |
AU2011218009A1 (en) | 2012-09-13 |
CA2790213A1 (en) | 2011-08-25 |
CN102869677A (zh) | 2013-01-09 |
TR201711271T4 (tr) | 2019-02-21 |
US20220227812A1 (en) | 2022-07-21 |
EP2536742A2 (en) | 2012-12-26 |
DK2536742T3 (en) | 2017-09-04 |
WO2011103311A2 (en) | 2011-08-25 |
US20200283479A1 (en) | 2020-09-10 |
EP2536742B1 (en) | 2017-07-19 |
PL2536742T3 (pl) | 2017-11-30 |
WO2011103311A3 (en) | 2011-12-29 |
MX2012009597A (es) | 2012-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX340234B (es) | Tratamiento para transtornos gastrointestinales. | |
MX2014001798A (es) | Tratamientos para trastornos gastrointestinales. | |
WO2006086653A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
WO2007101158A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
SG153824A1 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
WO2007022531A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
WO2008002971A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
MXPA05008097A (es) | Metodos y composiciones para el tratamiento de desordenes gastrointestinales. | |
WO2005016244A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
JP2011152140A5 (es) | ||
HK1199039A1 (en) | Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation 23-26- fsh | |
WO2007062168A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
IN2013MN01519A (es) | ||
WO2005074575A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
WO2006102069A3 (en) | Methods and compositions for the treatment of hypertension and gastrointestinal disorders | |
CL2014003144A1 (es) | Uso de mesalamina granulada para el tratamiento de un trastorno gastrointestinal tal como enfermedad del intestino irritable, enfermedad de crohn, colitis ulcerosa y gastroparesia, que comprende administrar dicha mesalamina granulada a un sujeto, el cual tiene un nivel de proteina c reactiva de al menos 2,2 mg/l. | |
WO2017019673A3 (en) | Methods for diagnosing and treating inflammatory bowel disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |